The futility study--Progress over the last decade
- PMID: 26123873
- PMCID: PMC4639404
- DOI: 10.1016/j.cct.2015.06.013
The futility study--Progress over the last decade
Abstract
We review the futility clinical trial design (also known as the non-superiority design) with respect to its emergence and methodologic developments over the last decade, especially in regard to its application to clinical trials for neurological disorders. We discuss the design's strengths as a programmatic screening device to weed out unpromising new treatments, its limitations and pitfalls, and a recent critique of the logic of the method.
Keywords: Futility design; Non-superiority design; Phase II trials; Screening program.
Copyright © 2015 Elsevier Inc. All rights reserved.
References
-
- Gehan EA. The determination of teh number of patients required in a preliminary and a follow-up trial of a new chmotherapeutic agent. J Chronic Dis. 1961;13:346–53. - PubMed
-
- Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics. 1979;35:775–83. - PubMed
-
- Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–51. - PubMed
-
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. - PubMed
-
- Betensky R. Alternative derivations of a rule for early stopping in favor of H0. The Amer Statistician. 2000;54:35–9.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
